Malt-1 inhibitor for treating glioma
GR20250100041APending Publication Date: 2026-08-12CLOUDPHARM PRIVATE CO +1
4 Cites 0 Cited by
Patent Information
- Application Number
- GR20250100041
- Authority / Receiving Office
- GR · GR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-01-20
- Publication Date
- 2026-08-12
Abstract
The present invention is directed to the field of personalized cancer care and treatment. In particular, a targeted approach is provided herein for treating neurological (e.g. brain) cancers (over)expressing mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with inhibitors of dipeptidyl peptidase-4 (DPP-4), also known as gliptins. Further provided herein are in vitro diagnostic methods for determining an increased probability that a neurological cancer of a human subject will respond to the treatment with a gliptin, the methods comprising determination of MALT1 expression status and, optionally, of DPP-4 expression status in a sample obtained from the subject.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Antitumor activity of liralipin and its novel applications
CN110496129B
Application of sitagliptin in preparation of drugs for treating glioma
CN111920816A
Gene group for prognosis prediction and treatment of glioblastoma, reagent, pharmaceutical preparation and construction method of scoring model
CN118374594A
Sitagliptin is a malt1 inhibitor
WO2025016548A1